The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET and 16:50 ET.
0844 GMT – AstraZeneca continues to outpace peer companies in earnings growth and should perform similarly well in 2026 despite a first-half that might be a bit bumpy, Morgan Stanley analysts Sarita Kapila and Thibault Boutherin write. The British pharma giant’s reiteration of guidance is likely to provide reassurance, the analysts say. The first half of next year might include challenges depending on trial results of competing drugs, but the group’s longer-term pipeline is underappreciated, they say. Shares are up 0.05% at 124.56 pounds.(william.gray@wsj.com)
Copyright ©2025 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8


